NCT01959672 - Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 6, 2013

Primary Completion Date

April 1, 2018

Study Completion Date

December 1, 2018

Conditions

Pancreatic AdenocarcinomaResectable Pancreatic CarcinomaStage I Pancreatic CancerStage IA Pancreatic CancerStage IB Pancreatic CancerStage II Pancreatic CancerStage IIA Pancreatic CancerStage IIB Pancreatic CancerStage III Pancreatic Cancer

Interventions

PROCEDURE

4-Dimensional Computed Tomography

Correlative studies

DRUG

Fluorouracil

Given IV

DRUG

Gemcitabine Hydrochloride

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Leucovorin Calcium

Given IV

DRUG

Nelfinavir Mesylate

Given PO

BIOLOGICAL

Oregovomab

Given IV

RADIATION

Stereotactic Body Radiation Therapy

Undergo SBRT

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgical resection

Trial Locations (1)

68198

University of Nebraska Medical Center, Omaha

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Nebraska

OTHER